Research programme: thrombin inhibitors - Thromgen

Drug Profile

Research programme: thrombin inhibitors - Thromgen

Alternative Names: Arg-Pro-Pro-Gly-Phe; MAP4-RPPGF; RPPGF; Thrombostatin™

Latest Information Update: 30 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Temple University; University of Michigan
  • Class
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Thrombosis

Most Recent Events

  • 26 Jul 2005 Preclinical trials in Acute coronary syndromes in USA (IV)
  • 26 Jul 2005 Preclinical trials in Thrombosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top